What are the exclusion criteria for HSCT for the treatment of scleroderma with pulmonary involvement?

Updated: Sep 09, 2019
  • Author: Sergio A Jimenez, MD, MACR, FACP, FRCP(UK Hon); Chief Editor: Herbert S Diamond, MD  more...
  • Print

Recommended exclusion criteria for HSCT include the following [159] :

  • FVC or hemoglobin‐adjusted DLCO of < 45% predicted
  • Pulmonary arterial hypertension
  • Cardiac insufficiency or involvement with systemic sclerosis
  • Renal insufficiency
  • Prior cyclophosphamide treatment of >6 months’ duration

Current studies of autologous stem cell transplantation, including a large randomized control study, the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, are ongoing.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!